Jun-Beom Lee1, Kyung-A Lee, Kyung-Yul Lee. 1. Department of Neurology, Severance Institute for Vascular and Metabolic Research, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Abstract
PURPOSE: Clopidogrel is a prodrug that requires transformation into an active metabolite by cytochrome P450 (CYP) in the liver in order to irreversibly inhibit the P2Y12 adenosine diphosphate platelet receptor. CYP2C19 polymorphism has been reported to correlate with reduced antiplatelet activity of clopidogrel in coronary artery disease. We assessed the association between CYP2C19 polymorphism and clopidogrel resistance in patients with cerebrovascular disease. MATERIALS AND METHODS: We retrospectively gathered data from patients who experienced cerebrovascular disease, received clopidogrel, and were tested for clopidogrel resistance and CYP2C19 polymorphism. Clopidogrel resistance was tested by the VerifyNow P2Y12 system, and the CYP2C19 polymorphism was tested by the Seeplex CYP2C19 ACE Genotyping system. Clopidogrel resistance was expressed in P2Y12 reaction units (PRU) and percent inhibition. High PRU and low percent inhibition suggests clopidogrel resistance. CYP2C19 polymorphisms were expressed as extensive, intermediate, and poor metabolizers. Clopidogrel resistance was assessed according to the subgroup of CYP2C19 polymorphism. RESULTS: A total of 166 patients were evaluated. The PRU values of extensive CYP2C19 metabolizers (195.0±84.9) were significantly lower than those of intermediate and poor metabolizers (237.9±88.0, 302.2±58.9). The percent inhibition of extensive metabolizers (44.6±21.8) was significantly higher than that of intermediate and poor metabolizers (30.5±21.5, 14.0±13.4). CONCLUSION: Intermediate and poor metabolizing CYP2C19 polymorphism is associated with reduced clopidogrel antiplatelet activity in patients with cerebrovascular disease. The clinical implications of this finding require further investigation.
PURPOSE:Clopidogrel is a prodrug that requires transformation into an active metabolite by cytochrome P450 (CYP) in the liver in order to irreversibly inhibit the P2Y12adenosine diphosphate platelet receptor. CYP2C19 polymorphism has been reported to correlate with reduced antiplatelet activity of clopidogrel in coronary artery disease. We assessed the association between CYP2C19 polymorphism and clopidogrel resistance in patients with cerebrovascular disease. MATERIALS AND METHODS: We retrospectively gathered data from patients who experienced cerebrovascular disease, received clopidogrel, and were tested for clopidogrel resistance and CYP2C19 polymorphism. Clopidogrel resistance was tested by the VerifyNow P2Y12 system, and the CYP2C19 polymorphism was tested by the Seeplex CYP2C19 ACE Genotyping system. Clopidogrel resistance was expressed in P2Y12 reaction units (PRU) and percent inhibition. High PRU and low percent inhibition suggests clopidogrel resistance. CYP2C19 polymorphisms were expressed as extensive, intermediate, and poor metabolizers. Clopidogrel resistance was assessed according to the subgroup of CYP2C19 polymorphism. RESULTS: A total of 166 patients were evaluated. The PRU values of extensive CYP2C19 metabolizers (195.0±84.9) were significantly lower than those of intermediate and poor metabolizers (237.9±88.0, 302.2±58.9). The percent inhibition of extensive metabolizers (44.6±21.8) was significantly higher than that of intermediate and poor metabolizers (30.5±21.5, 14.0±13.4). CONCLUSION: Intermediate and poor metabolizing CYP2C19 polymorphism is associated with reduced clopidogrel antiplatelet activity in patients with cerebrovascular disease. The clinical implications of this finding require further investigation.
Authors: Giuseppe Patti; Annunziata Nusca; Fabio Mangiacapra; Laura Gatto; Andrea D'Ambrosio; Germano Di Sciascio Journal: J Am Coll Cardiol Date: 2008-09-30 Impact factor: 24.094
Authors: Alex Malinin; Alex Pokov; Malcolm Spergling; Anthony Defranco; Kenneth Schwartz; Dianne Schwartz; Ehtisham Mahmud; Dan Atar; Victor Serebruany Journal: Thromb Res Date: 2006-03-24 Impact factor: 3.944
Authors: Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine Journal: N Engl J Med Date: 2008-12-22 Impact factor: 91.245
Authors: Thomas Gremmel; Sabine Steiner; Daniela Seidinger; Renate Koppensteiner; Simon Panzer; Christoph W Kopp Journal: Heart Date: 2009-08-16 Impact factor: 5.994
Authors: Hong Chen; Zhong-Yang Shen; Wang Xu; Tie-Yan Fan; Jun Li; Yuan-Fu Lu; Ming-Liang Cheng; Jie Liu Journal: World J Gastroenterol Date: 2014-07-14 Impact factor: 5.742
Authors: M Lin; M Todaro; J Chan; L Churilov; W S Zhu; S Ramdave; P J Mitchell; R J Dowling; P Kwan; B Yan Journal: AJNR Am J Neuroradiol Date: 2015-09-03 Impact factor: 3.825
Authors: Sang Won Han; Yong-Jae Kim; Seong Hwan Ahn; Woo-Keun Seo; Sungwook Yu; Seung-Hun Oh; Hyo Suk Nam; Hye-Yeon Choi; Sung Sang Yoon; Seo Hyun Kim; Jong Yun Lee; Jun Hong Lee; Yang-Ha Hwang; Kee Ook Lee; Yo Han Jung; Jun Lee; Sung-Il Sohn; Youn Nam Kim; Kyung-A Lee; Cheryl D Bushnell; Kyung-Yul Lee Journal: J Stroke Date: 2017-09-29 Impact factor: 6.967